-
Tytuł:
-
[Management of the bleeding risk associated with antiplatelet agents].
-
Autorzy:
-
Martin AC; Service de cardiologie, hôpital d'instruction des armées Percy, 92140 Clamart, France; Inserm UMRS 1140, faculté de pharmacie, université Paris Descartes, 75006 Paris, France. Electronic address: .
Houssany-Pissot S; Service de cardiologie, hôpital d'instruction des armées Percy, 92140 Clamart, France.
Zlotnik D; Inserm UMRS 1140, faculté de pharmacie, université Paris Descartes, 75006 Paris, France.
Taylor G; Service d'anesthésie réanimation, fondation Adolphe-de-Rothschild, 75019 Paris, France.
Godier A; Inserm UMRS 1140, faculté de pharmacie, université Paris Descartes, 75006 Paris, France; Service d'anesthésie réanimation, fondation Adolphe-de-Rothschild, 75019 Paris, France.
-
Transliterated Title:
-
Prise en charge du risque hémorragique associé aux agents antiplaquettaires.
-
Źródło:
-
La Revue de medecine interne [Rev Med Interne] 2017 Jul; Vol. 38 (7), pp. 467-473. Date of Electronic Publication: 2017 May 17.
-
Typ publikacji:
-
Journal Article; Review
-
Język:
-
French
-
Imprint Name(s):
-
Publication: Paris : Elsevier
Original Publication: Paris : Baillière, [1980-
-
MeSH Terms:
-
Drug-Related Side Effects and Adverse Reactions/*therapy
Hemorrhage/*chemically induced
Hemorrhage/*therapy
Platelet Aggregation Inhibitors/*therapeutic use
Adenosine/administration & dosage ; Adenosine/adverse effects ; Adenosine/analogs & derivatives ; Aspirin/administration & dosage ; Aspirin/adverse effects ; Clopidogrel ; Drug-Related Side Effects and Adverse Reactions/prevention & control ; Humans ; Platelet Aggregation Inhibitors/adverse effects ; Risk Factors ; Ticagrelor ; Ticlopidine/administration & dosage ; Ticlopidine/adverse effects ; Ticlopidine/analogs & derivatives
-
Contributed Indexing:
-
Keywords: Antidote; Antiplaquettaire; Antiplatelet agent; Bleeding; Hémorragie; Neutralisation; Platelet transfusion; Reversal; Transfusion plaquettaire
-
Substance Nomenclature:
-
0 (Platelet Aggregation Inhibitors)
A74586SNO7 (Clopidogrel)
GLH0314RVC (Ticagrelor)
K72T3FS567 (Adenosine)
OM90ZUW7M1 (Ticlopidine)
R16CO5Y76E (Aspirin)
-
Entry Date(s):
-
Date Created: 20170522 Date Completed: 20171031 Latest Revision: 20181202
-
Update Code:
-
20240105
-
DOI:
-
10.1016/j.revmed.2017.01.013
-
PMID:
-
28528236
-
Like all antithrombotic drugs, antiplatelet agents expose to a risk of bleeding complications. Clinical research has extensively focused on the efficacy of these drugs to reduce ischemic events. The bleeding risk associated with them was solely considered as an inevitable and acceptable complication. When two new potent P2Y12-receptor inhibitors, prasugrel and ticagrelor, were marketed, the risk of major bleeding increased. These new agents have modified the balance between the absolute risk reduction in ischemic events and the absolute risk increase in bleeding events. This paper is an update on the bleeding risk assessment associated with antiplatelet agents. It discusses the place of platelet function monitoring, and the optimal management of bleeding complications. It addresses the challenging issue of reversal of antiplatelet therapy, focusing especially on ticagrelor, which pharmacodynamics complicate bleeding management.
(Copyright © 2017 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier SAS. All rights reserved.)